EU/3/16/1718

About

On 29 August 2016, orphan designation (EU/3/16/1718) was granted by the European Commission to Richardson Associates Regulatory Affairs Ltd, United Kingdom, for cannabidiol for the treatment of graft-versus-host disease.

The sponsorship was transferred to Salzman Group Ltd, United Kingdom, in July 2018.

Key facts

Active substance
Cannabidiol
Disease / condition
Treatment of graft-versus-host disease
Date of first decision
29/08/2016
Outcome
Positive
EU designation number
EU/3/16/1718

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Salzman Group Ltd
Flat 5, 131 Fellows Road
London NW3 3JJ
United Kingdom
Tel. +44 7743 406834

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating